Search
Close this search box.

ERS Genomics and Cellular Engineering Technologies collaborating

ERS Genomics and Cellular Engineering Technologies have entered into a CRISPR-Cas9 license agreement.

Under the agreement, Cellular Engineering Technologies licences the rights from Dublin-based ERS Genomics Ltd. to develop, manufacture and commercialise next-generation stem cell lines using the CRISPR-Cas9 technology initially patented by Emmanuelle Charpentier.

Cell manufacturing specialist Cellular Engineering Technologies (CET) will use the non-exclusive license to support research organizations at the interface of stem cell research and preclinical drug discovery. CET’s portfolio includes its proprietary induced pluripotent stem cell technology, which is both virus- and oncogene-free to improve cell line genetic stability, safety, and reproducibility in drug discovery workflows for cell and gene therapies.

The license from ERS Genomics will allow CET to develop, manufacture and commercialize next generation stem cell lines using CRISPR/Cas9 technology.  Alan Moy, MD, CEO and Co-Founder of CET, commented: “This [agreement] will offer greatly improved cells to produce therapeutic biologics, viral vectors for cell and gene therapy, and vaccines for both the human and animal health sectors.” 

Financial details of the agreement are not disclosed.